



November 2007

HVTN Global Trial Sites

The HIV Vaccine Trials Network (HVTN) is the largest clinical trials program devoted to the development and testing of preventive HIV vaccines worldwide. The Network's investigators, who are leaders in HIV and vaccine research in their countries, work collectively as a driving force in the search for an effective HIV vaccine.

The HIV Vaccine Trials Network is supported through a cooperative agreement with the National Institute of Allergy and Infectious Diseases (NIAID), which is a component of the U.S. National Institutes of Health (NIH). The Network and NIAID have a close, cooperative working relationship, with shared attention to intellectual and scientific issues.

Open Study Protocols

The HVTN integrates clinical trials development and management with state-of-the-art laboratory testing and development of new immunological assays to establish correlates of protection against HIV infection. HVTN protocol development teams assist companies and inventors of candidate HIV vaccines in expediting clinical development. None of the vaccine candidates can result in HIV infection. More than twenty vaccine trial concepts are in progress or in development. The HVTN is currently conducting 15 clinical trials of HIV vaccine candidates. These are summarized in the following table:

Protocol Number	Developer	Vaccine design	Enrollment	Sites	Targeted number of participants
049	Chiron / NOVAD	DNA + protein	Closed to accrual ¹	USA	96
050	Merck	Adenovirus	Closed to accrual	USA, international	435
055	Therion	MVA + fowlpox	Closed to accrual	USA, Brazil	150
060	Wyeth	DNA + IL-12 DNA	Closed to accrual	USA, Thailand	144
063	Wyeth	DNA + IL-12 DNA + IL-15 DNA	Closed to accrual	USA, Brazil	120
064	Pharmexa-Epimmune	DNA + HTL	Closed to accrual	USA	84
065	GeoVax	DNA + MVA	Enrolling	USA	120
067	Pharmexa-Epimmune/Bavarian Nordic	DNA+ MVA	Enrolling	USA	108
069	NIH VRC	DNA + Adenovirus	Closed to accrual	USA, Peru	90
070	UPenn / Wyeth	DNA + Adenovirus	Enrolling	USA	120
071	Merck	Adenovirus	Closed to accrual	USA	35
073	South African AIDS Vaccine Initiative (SAAVI)	DNA + MVA	Study setup	USA, South Africa	48
204	NIH VRC	DNA	Closed to accrual	USA, international	480
502	Merck	Adenovirus	Closed to accrual	USA, international	3000
503	Merck	Adenovirus	Closed to accrual	South Africa	801

¹ Closed to accrual=no new participants enrolled

The HVTN is committed to coordination, information sharing and global collaboration to find an effective HIV vaccine. The Network's HIV Vaccine Trial Units are located at leading research institutions in 28 cities on five continents. The Network's headquarters are at Fred Hutchinson Cancer Research Center in Seattle, Washington.

At each clinical trial site, the community plays a significant role in the development and execution of the vaccine research through the work of a Community Advisory Board (CAB) comprising members of the community interested in HIV vaccine research.

CAB members come from all walks of life and often include former vaccine trial participants, people living with HIV, faith leaders and community activists. Each CAB holds regular meetings to review local vaccine research efforts and to ensure that the community participating in the research is treated ethically and fairly. Each committee of the HVTN includes a CAB representative to ensure that the community is represented in all aspects of the HVTN's work.



HVTN Trial Sites and Principal Investigators

Brazil

Rio de Janeiro: Hospital Escola São Francisco de Assis; Drs. Mauro Schechter & Paulo Barroso

São Paulo: Centro de Referencia em referencia em DST/AIDS; Drs. Artur Kalichman & Regina Barbosa. Universidade Federal de São Paulo; Dr. Esper Kallas

Dominican Republic

Santo Domingo: Instituto Dermatológico y Cirugia de la Piel; Drs. Yeycy Donastorg, Claudio Vólquez. Lcda. Margarita de Quiñones & Lic. Luis Moreno

Haiti

Port-au-Prince: Cornell-GHESKIO; Drs. Jean William Pape, Marie-Marcelle Deschamps, Dan Fitzgerald, Sonia Jean, Warren Johnson, Patrice Joseph & Sandy Nerette

Jamaica

Kingston: Jamaica Ministry of Health; Dr. Peter Figueroa

Peru

Iquitos: Asociación Civil Selva Amazónica; Dr. Martín Casapia

Miraflores/Lince (Lima): Asociación Civil Impacta Salud y Educación (IMPACTA); Drs. Jorge Sánchez, Javier Lama, Alberto LaRosa, Pedro Gonzales & Pedro Goicochea

South Africa

Cape Town: Desmond Tutu HIV Centre; Dr. Linda-Gail Bekker

Durban: CAPRISA; Drs. Koleka Mlisana & Salim S. Abdool Karim

KOSH (Klerksdorp): Aurum Institute for Health Research; Dr. Gavin Churchyard

Medunsa: The Medical University of Southern Africa (MEDUNSA) HIV Vaccine Research Unit; Drs. Maphoshane Nchabeleng, Matsontso Mathebula & Anwar Hoosen

Soweto: Chris Hani Baragwanath Hospital; Drs. Glenda Gray, James McIntyre & Eftyhia Vardas

Switzerland

Lausanne, Switzerland: CHUV Hospital/CHUV; Dr. Giuseppe Pantaleo

Thailand

Chiang Mai: Research Institute for Health Sciences-Chiang Mai University; Drs. Thira Sirisanthana, Vinai Suriyanon & Natthapol Kosashunhanan

United States

Atlanta, Georgia: Emory University; Drs. Mark Mulligan, Paul Spearman, Srilatha Edupuganti & Carlos Del Rio

Baltimore, Maryland: University of Maryland at Baltimore; Dr. William Blattner

Birmingham, Alabama: University of Alabama Vaccine Research Clinic; Drs. Paul Goepfert & Scott Parker

Boston, Massachusetts: Brigham & Women's Hospital; Drs. Raphael Dolin & Lindsay Baden. Fenway Community Health Center; Drs. Kenneth Mayer & Daniel Cohen

Raleigh, North Carolina: University of North Carolina at Chapel Hill; Dr. Kristine Patterson

Chicago, Illinois: University of Illinois-Chicago; Drs. Richard Novak, Larry Ouellet & David McKirnan

Nashville, Tennessee: Vanderbilt University; Drs. Peter Wright & Spyros Kalamis

New York, New York: Project Achieve – Bronx & Union Square; Dr. Beryl Koblin. Columbia University; Drs. Scott Hammer & Magda Sobieszcyk

Philadelphia, Pennsylvania: University of Pennsylvania; Drs. David Metzger, Ian Frank, Pablo Tebas & Lisa Maslankowski

Rochester, New York: University of Rochester; Drs. Michael Keefer, Christine M. Hay & Xia Jin

San Francisco, California: SF Department of Public Health; Drs. Susan Buchbinder & Jonathan Fuchs

San Juan, Puerto Rico: University of Puerto Rico School of Medicine; Drs. Carmen Zorrilla & Lydia Santiago

Seattle, Washington: Fred Hutchinson Cancer Research Center; Drs. Julie McElrath & Connie Celum